Toronto, Canada

Jan Delabie


 

Average Co-Inventor Count = 23.1

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:

goldMedal6 out of 3,435 
 
National Institutes of Health, a Component of the US Dept. of Health & Human Services
 patents
silverMedal6 out of 21 
 
Hospital Clinic De Barcelona
 patents
bronzeMedal5 out of 61 
 
British Columbia Cancer Agency Branch
 patents
45 out of 47 
 
UniversitÄt De Barcelona
 patents
55 out of 6 
 
Julius-maximilians-university of Wurzburg
 patents
65 out of 11 
 
Oslo University Hospital Hf
 patents
74 out of 972 
 
University of Arizona
 patents
84 out of 730 
 
University of Nebraska
 patents
94 out of 504 
 
Oregon Health & Science University
 patents
103 out of 1,036 
 
The Cleveland Clinic Foundation
 patents
112 out of 1,742 
 
Mayo Foundation for Medical Education and Research
 patents
122 out of 88 
 
University of London
 patents
132 out of 970 
 
University of Rochester
 patents
141 out of 3 
 
British Columbia Cancer Agency
 patents
151 out of 1 
 
Universitat De Barceloa
 patent
161 out of 1 
 
Institut D'investigacions Biomédiques Pi I Sunyer (Idibaps)
 patent
171 out of 1 
 
Robert Bosch Gesellschaft Feuer Medizinische Forshung Mbh
 patent
181 out of 639 
 
City of Hope
 patents
191 out of 2 
 
Fundacio Clinic
 patents
where one patent can have more than one assignee

Years Active: 2020-2023

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Jan Delabie: A Brilliant Mind in Lymphoma Research and Treatment

Jan Delabie, a prominent figure in the field of medical innovation, is a Toronto-based inventor and researcher specializing in distinguishing between lymphoma types based on gene expression measurements. With an impressive track record of 7 patents, his groundbreaking methods have revolutionized the field of lymphoma subtyping and treatment.

One of Delabie's latest patents, titled "Method for determining lymphoma type and providing treatment," focuses on utilizing gene expression signatures to differentiate between various lymphoma types. Particularly, the invention distinguishes between primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) subtypes. The distinctions identified through this method are crucial in developing effective treatment strategies for patients suffering from different forms of lymphoma.

In addition, Delabie has also patented the "Method for subtyping lymphoma types by means of expression profiling." This invention enables the selection of suitable treatment options for patients diagnosed with specific subtypes of lymphomas, such as activated B cell-like diffuse large B cell lymphoma (ABC DLBCL), germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL), Burkitt lymphoma (BL), and mantle cell lymphoma (MCL). By analyzing digital gene expression data obtained from biopsy samples, this method facilitates personalized treatment plans tailored to individual patients.

Throughout his career, Jan Delabie has collaborated with esteemed institutions and organizations. Notably, he has worked with the United States Department of Health and Human Services, representing the country's dedication to advancing medical research and innovation. Furthermore, Delabie has also contributed to the research efforts of Arizona State University, harnessing the power of collaboration to further scientific progress.

Among Jan Delabie's esteemed colleagues, Wing C Chan and Dennis Weisenburger stand out. These individuals have played an integral role in assisting Delabie in his research endeavors and have contributed significantly to the development of these patented methods.

Jan Delabie's passion for innovation and his commitment to advancing medical treatments for lymphomas have solidified his place as a notable figure in the field of medical research. With his groundbreaking inventions, patients diagnosed with lymphoma can hope for more effective treatment options, improving their overall quality of life.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…